Brielle Benyon

Brielle Benyon

Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.

Follow Brielle on Twitter @Brielle_Benyon.

Articles by Brielle Benyon

Lung cancer is the leading cause of cancer-related death for women in the United States, but often does not get as much attention as other malignancies. In an effort to change that, and to one day decrease the number of women who are dying from the disease, the bipartisan Women and Lung Cancer Research and Preventative Services Act was reintroduced into Congress.

So, wouldn't it be nice to have a quantitative way to say how deep the remission is? Historically, it’s been felt that if you just scratch the surface and get below the 5 percent blast level, you’re probably going to relapse. And if you get deeper, you might not.

Racial and socioeconomic status disparities can affect all types of lung cancer treatment – including surgery, chemotherapy and radiation. However, researchers may not be aware of this, since many of these groups are underrepresented in lung cancer clinical trials.

To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can be combined with other agents to benefit patients.

“As the population of cancer survivors continues to grow, so does the importance of addressing the long-term sequelae of cancer treatment,” the authors wrote. “This hearing loss can result in multifaceted decrease in quality of life, and in pediatric patients it can impact social and academic development.”

While patients with chronic lymphocytic leukemia (CLL) tend to have long life expectancies, with many prescribed to a “watch-and-wait” approach, a recent study by the Cancer Support Community (CSC) found that more than half of patients living with the disease reported that having CLL affects their viewpoints regarding their life expectancy.